Tevogen Bio Holdings Inc. has announced the development of the alpha version of PredicTcell™, a proprietary machine learning model created in collaboration with Microsoft and Databricks. This model is designed to significantly expedite target analysis in immunotherapy research, potentially reducing drug development costs by billions. The announcement aligns with the U.S. government's AI Action Plan, which emphasizes rapid scientific AI innovation in the healthcare sector. As of now, Tevogen has not specified if these research results have been formally presented at any scientific conferences or publications.